China SXT Pharmaceuticals, Inc.
SXTC
$1.49
-$0.08-5.10%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 455.70K | 455.70K | 414.70K | 414.70K | 494.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 455.70K | 455.70K | 414.70K | 414.70K | 494.50K |
| Cost of Revenue | 339.40K | 339.40K | 347.40K | 347.40K | 361.60K |
| Gross Profit | 116.30K | 116.30K | 67.40K | 67.40K | 132.80K |
| SG&A Expenses | 1.14M | 1.14M | 386.50K | 386.50K | -3.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.48M | 1.48M | 733.90K | 733.90K | -3.13M |
| Operating Income | -1.02M | -1.02M | -319.10K | -319.10K | 3.63M |
| Income Before Tax | -1.25M | -1.25M | -401.30K | -401.30K | 3.30M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.25M | -1.25M | -401.30K | -401.30K | 3.30M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.25M | -1.25M | -401.30K | -401.30K | 3.30M |
| EBIT | -1.02M | -1.02M | -319.10K | -319.10K | 3.63M |
| EBITDA | -1.01M | -1.01M | -284.90K | -284.90K | 3.68M |
| EPS Basic | -0.51 | -0.51 | -0.99 | -0.99 | 21.40 |
| Normalized Basic EPS | -0.32 | -0.32 | -0.62 | -0.62 | 14.23 |
| EPS Diluted | -0.51 | -0.51 | -0.99 | -0.99 | 21.40 |
| Normalized Diluted EPS | -0.32 | -0.32 | -0.62 | -0.62 | 14.23 |
| Average Basic Shares Outstanding | 2.44M | 2.44M | 403.90K | 403.90K | 154.20K |
| Average Diluted Shares Outstanding | 2.44M | 2.44M | 403.90K | 403.90K | 154.20K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |